Drug intelligence / Profile preview

hydrocortisone + polymyxin B

Development stage: Unknown
Modality: Small Molecules
Administration: Otic, Ophthalmic, Topical

Overview

Hydrocortisone + polymyxin B is a combination medication containing an antibiotic (polymyxin B) and a corticosteroid (hydrocortisone). Polymyxin B works by disrupting the outer cell membrane of Gram-negative bacteria, binding and neutralizing lipopolysaccharide, and inhibiting bacterial cell respiration. Hydrocortisone reduces inflammation by activating natural substances in the affected area to reduce swelling, redness, and itching. This combination is primarily used to treat infections of the ear canal, eye infections, and certain skin infections.

Brand names: CortisporinCasporyn HCCort-BioticCortomycinOti-SonePedioticAntibiotic OticOticair

Targets

GR (Glucocorticoid receptor)LPS (Lipopolysaccharide)

Beyond the preview

Go deeper on hydrocortisone + polymyxin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrocortisone + polymyxin B.

Explore the full profile